Article info
Experimental therapeutics – preclinical
M17 Targeting Dopamine D1-histamine H3 Receptor Heteromers As A Therapeutical Strategy To Prevent Cognitive Deficits And Neurodegeneration In Huntington’s Disease
Citation
M17 Targeting Dopamine D1-histamine H3 Receptor Heteromers As A Therapeutical Strategy To Prevent Cognitive Deficits And Neurodegeneration In Huntington’s Disease
Publication history
- First published September 17, 2014.
Online issue publication
February 26, 2018
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2014, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions